Core Viewpoint - Kangmei Pharmaceutical Co., Ltd. reported a revenue increase of 4.17% year-on-year for the first half of 2025, with total revenue reaching approximately 2.58 billion RMB, and a net profit attributable to shareholders of approximately 16.90 million RMB, reflecting a 7.24% increase compared to the previous year [2][3]. Company Overview and Financial Indicators - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine and related products [3]. - As of June 30, 2025, the company's total assets amounted to approximately 13.64 billion RMB, a decrease of 1.11% from the previous year [2]. - The net assets attributable to shareholders were approximately 7.19 billion RMB, showing a slight increase of 0.23% [2]. Industry and Business Analysis - The pharmaceutical industry is a crucial part of China's economy, characterized by high investment, high risk, and strict regulations. The demand for healthcare is increasing due to economic growth and an aging population [3][4]. - Kangmei Pharmaceutical is positioned as a leading enterprise in the traditional Chinese medicine sector, with a comprehensive operational system covering the entire supply chain from cultivation to sales [4][5]. - The company has established eight modern production bases for traditional Chinese medicine across various provinces, with a production capacity exceeding 20,000 specifications of traditional Chinese medicine pieces [4][5]. Main Business and Products - The core business of the company includes the production and sales of traditional Chinese medicine pieces, with a focus on integrating the entire industry chain [5][6]. - Key products include traditional Chinese medicine pieces, proprietary Chinese medicines, chemical drugs, health foods, and various food products [5][6]. - The company has developed a range of patented products, including 36 national patent products and 13 provincial high-tech products [5][6]. Operational Model - The company employs a comprehensive procurement model for traditional Chinese medicine materials, ensuring quality and cost-effectiveness through strategic partnerships and direct sourcing from production areas [7][8]. - The sales model includes direct sales to hospitals, commercial wholesale, and a multi-channel marketing network that integrates online and offline sales [9][10]. Recent Developments and Innovations - The company has been actively enhancing its "smart pharmacy" model, integrating modern technology with traditional practices to improve service efficiency and patient care [14][16]. - Kangmei Pharmaceutical has successfully signed contracts with over 1,200 medical institutions, providing high-quality traditional Chinese medicine services to millions of patients [16][21]. - The company is also focusing on the development of a health management platform, integrating medical and wellness services to enhance patient care [21][22].

Core Viewpoint - The company is preparing for its 2024 Annual General Meeting, focusing on governance, financial performance, and strategic initiatives for growth in the pharmaceutical automation sector. Group 1: Meeting Procedures and Governance - The meeting will take place on June 25, 2025, at 14:00 in Shanghai, combining on-site and online voting methods [6][12]. - Attendees must register and present identification to confirm their eligibility to participate [2][3]. - The meeting will include a series of agenda items, including the presentation of reports and voting on various proposals [6][7]. Group 2: Financial Performance - The company reported a net profit of 32,520,676.27 yuan for the year, a decrease of 45.80% compared to the previous year [11][24]. - The total assets of the company reached 146,601.12 million yuan, reflecting growth due to market expansion efforts [24]. - The company has decided not to distribute cash dividends for 2024, with retained earnings of 233,162,211.41 yuan to be reinvested for future growth [10][11]. Group 3: Industry Context and Company Strategy - The pharmaceutical automation industry is experiencing rapid growth driven by technological advancements and increasing healthcare demands [12][13]. - The company is positioned as a provider of comprehensive solutions in the pharmaceutical automation sector, focusing on product design, development, and after-sales service [13][14]. - Strategic initiatives include expanding into international markets, enhancing partnerships with leading retail pharmacies, and developing smart pharmacy solutions [14][25]. Group 4: Future Plans and Innovations - The company aims to enhance its R&D capabilities and expand its market presence, particularly in overseas markets [30][31]. - Plans include leveraging AI technology to improve healthcare services and developing innovative products tailored to market needs [31]. - The company is committed to maintaining strong investor relations and ensuring transparent communication regarding its strategic direction and financial performance [29][31].